- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients ; volume:12 ; number:3 ; year:2018 ; pages:608-616
Case reports in gastroenterology ; 12, Heft 3 (2018), 608-616
- Creator
-
Silva, Elen Farinelli de Campos
Baima, Júlio Pinheiro
de Barros, Jaqueline Ribeiro
Renosto, Fernanda Lofiego
de Sibia, Carina de Fatima
Saad-Hossne, Rogério
Sassaki, Ligia Yukie
- DOI
-
10.1159/000493921
- URN
-
urn:nbn:de:101:1-2019012323210427597475
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Silva, Elen Farinelli de Campos
- Baima, Júlio Pinheiro
- de Barros, Jaqueline Ribeiro
- Renosto, Fernanda Lofiego
- de Sibia, Carina de Fatima
- Saad-Hossne, Rogério
- Sassaki, Ligia Yukie
Other Objects (12)
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers
Crohn’s appendicitis
Monitoring of anti-TNF biological treatments
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers
Crohn’s appendicitis
Monitoring of anti-TNF biological treatments
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers
Crohn’s appendicitis